Investment analysts at StockNews.com initiated coverage on shares of MediciNova (NASDAQ:MNOV - Get Free Report) in a note issued to investors on Friday. The firm set a "hold" rating on the biopharmaceutical company's stock.
Separately, D. Boral Capital assumed coverage on MediciNova in a research report on Monday, December 2nd. They set a "buy" rating and a $9.00 price target on the stock.
View Our Latest Stock Report on MNOV
MediciNova Stock Performance
Shares of MediciNova stock traded down $0.03 during trading on Friday, reaching $1.96. The company had a trading volume of 29,935 shares, compared to its average volume of 33,456. The company has a market cap of $96.13 million, a price-to-earnings ratio of -9.33 and a beta of 0.84. MediciNova has a fifty-two week low of $1.12 and a fifty-two week high of $2.55. The firm's fifty day moving average is $2.03 and its 200-day moving average is $1.73.
Hedge Funds Weigh In On MediciNova
An institutional investor recently bought a new position in MediciNova stock. Jane Street Group LLC purchased a new stake in shares of MediciNova, Inc. (NASDAQ:MNOV - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 14,138 shares of the biopharmaceutical company's stock, valued at approximately $30,000. 9.90% of the stock is owned by institutional investors.
MediciNova Company Profile
(
Get Free Report)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Read More
Before you consider MediciNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.
While MediciNova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
